Sugi Predict

Sugi Predict / Compounds / SCHEMBL439062

SCHEMBL439062

SCHEMBL439062

Cc1ccc(S(=O)(=O)OC[C@H]2CO2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.54
▸ WDR77 Q9BQA1 1/20 0.54
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.50
▸ PKM P14618 2/20 0.50
▸ GAA P10253 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ CYP2D6 P10635 4/20 0.46
▸ CYP3A4 P08684 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ GLA P06280 1/20 0.41
▸ STAT3 P40763 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ SLC12A2 P55011 1/20 0.40
▸ SLC12A5 Q9H2X9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL439063 1.00 PRMT5 (0.54) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL450879 1.00 PRMT5 (0.54) PRMT5WDR77MEN1KMT2AALDH1A1
Methane SCHEMBL6982432 0.98 PRMT5 (0.52) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL3744218 0.92 PRMT5 (0.48) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL8065579 0.92 PRMT5 (0.48) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL3744219 0.92 PRMT5 (0.48) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL3748651 0.92 PRMT5 (0.48) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL8068113 0.92 PRMT5 (0.48) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL3745429 0.92 PRMT5 (0.48) PRMT5WDR77MEN1KMT2AALDH1A1
SCHEMBL25305831 0.91 PRMT5 (0.47) PRMT5WDR77MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116925136-A Preparation method of (R) -1, 2-distearoyl phosphatidyl glycerol 苏州东南药业股份有限公司 2023-10-24 — — CN claimed
CN-110317621-B Method for controllably promoting medium and low temperature asphalt stabilization through multi-bond cooperation 中国科学院山西煤炭化学研究所 2021-05-25 — — CN claimed
CN-112047697-A High-performance modified recycled concrete and preparation method thereof 瑞普环保新材料(广州)有限公司 2020-12-08 — — CN claimed
CN-110317621-A A kind of collaboration of multikey is controllable promote in the stabilized method of soft pitch 中国科学院山西煤炭化学研究所 2019-10-11 — — CN claimed
CN-106582334-A Composite reverse osmosis membrane and preparation method and application thereof 中国石油化工股份有限公司 2017-04-26 — — CN claimed
CN-101981023-A Process for preparing benzo-fused dioxin derivatives JANSSEN PHARMACEUTICA NV 2011-02-23 — — CN claimed
EP-2280951-A2 PROCESSES FOR THE PREPARATION OF BENZO-FUSED DIOXIN DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2011-02-09 — — EP claimed
WO-2009120192-A2 PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES JASSEN PHARMACEUTICA, N.V. (BE) 2009-10-01 — — WO claimed
US-20090247618-A1 PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES JANSSEN PHARMACEUTICA, N.C. (BE) 2009-10-01 — — US claimed
EP-0485894-B1 Methods for the preparation of semi-synthetic diastereomerically pure N-glycidyl-anthracyclines HOECHST AG (DE) 1999-02-03 — — EP claimed
EP-0242265-B1 1,5-BENZOTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTICAL USE SYNTHELABO (FR) 1991-05-29 — — EP claimed
CN-122080069-A Phospholipid compounds and uses thereof — 2026-05-26 — — CN disclosed
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 — — US disclosed
CN-121044995-A Preparation method of androgen receptor N-terminal domain inhibitor RALANITEN TRIACETATE and intermediate RALANITEN thereof 常州大学 2025-12-02 — — CN disclosed
CN-1036766-A 4-substituted pyrazolecarboxylic [3,4-d] pyrimidine derivatives ORTHO PHARMA CORP (US) 1989-11-01 — — CN disclosed
US-4876257-A 6-Substituted purinyl piperazine derivatives useful as cardiotonic and antiarrhythmic agents ORTHO PHARMACEUTICAL CORPORATION (US) 1989-10-24 — — US disclosed
EP-0331511-A1 6-Substituted purinyl piperazine derivatives ORTHO PHARMACEUTICAL CORPORATION (US) 1989-09-06 — — EP disclosed
EP-0331510-A2 4-Substituted pyrazolo[3,4-d]pyrimidine derivatives ORTHO PHARMACEUTICAL CORPORATION (US) 1989-09-06 — — EP disclosed
EP-0269258-A2 Process for the preparation of a pyrrolidinol compound A.H. ROBINS COMPANY, INCORPORATED (US) 1988-06-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX PRMT5 3539/4885WDR77 3221/4885MEN1 4583/4885
US-20090247618-A1 PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES CYP3A4, CYP3A5, CYP1A2 PRMT5 2752/4885WDR77 1997/4885MEN1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.